Apeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API

Stock News

11/10

Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

Venlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.

The approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1154494538"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154494538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154494538?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154494538","market":"fut","top_or_hot":-1,"title":"Apeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API","media":"Stock News","content":"<p>Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).</p>\n<p>Venlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.</p>\n<p>The approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-11-10 16:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).</p>\n<p>Venlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.</p>\n<p>The approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"孖展沽空","start_time":0,"source_url":"","article_id":"1154494538","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154494538","pubTimestamp":1762764381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0188":"融资融券","CEP":"Cantor Equity Partners Inc","BK0060":"抗癌","000739":"普洛药业","BK0239":"医药制造"},"translate_title":"Apeloa Pharmaceutical(000739.SZ)获得盐酸文拉法辛原料药欧洲CEP证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CEP":1,"000739":1},"content_text":"Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).\nVenlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.\nThe approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}